Quanterix Unveils Biomarker Detection Innovations at J.P. Morgan Healthcare Conference 2025

Quanterix Showcases Innovations in Biomarker Detection at Upcoming Healthcare Conference

Quanterix Corporation, a leader in ultrasensitive biomarker detection based in Billerica, Massachusetts, prepares for a significant presentation at the 43rd Annual J.P. Morgan Healthcare Conference, scheduled from January 13 to 16, 2025. President and CEO Masoud Toloue is set to highlight the company's advancements in biomarker quantification during his speech on January 15 at 4:30 p.m. PST. This prestigious conference serves as a platform for Quanterix to share its innovative technologies and engage in meaningful discussions with institutional investors through one-on-one meetings, emphasizing its commitment to advancing healthcare solutions.

At the core of Quanterix's offerings is its proprietary Simoa® technology, which allows for the detection and quantification of proteins at levels far below traditional methods. This unparalleled sensitivity positions Quanterix as a frontrunner in the biomarker detection field, enabling researchers to make significant strides in understanding various diseases. The company’s advanced precision instruments and digital immunoassay technology play a crucial role in its success, facilitating research across diverse medical fields, including neurology, oncology, immunology, cardiology, and infectious diseases. Over the last two decades, Quanterix has contributed to more than 3,100 peer-reviewed publications, underscoring its impact on scientific progress and healthcare innovation.

Quanterix's commitment to advancing research is further supported by its CLIA-certified Accelerator laboratory, which provides essential services for clinical and translational studies. The laboratory enhances the company’s capacity to support researchers and healthcare professionals in their quest for improved disease understanding and management. As Quanterix prepares for its presentation at the J.P. Morgan Healthcare Conference, it aims not only to showcase its technological advancements but also to foster collaborations that could lead to groundbreaking discoveries in biomarker research.

In addition to its conference presentation, Quanterix offers interested parties the opportunity to access a live webcast of the speech via its website, with a replay available for a limited time afterward. The company also acknowledges the inherent risks and uncertainties associated with its forward-looking statements, as outlined in its filings with the U.S. Securities and Exchange Commission. For further details on Quanterix’s innovative technologies and updates, stakeholders can visit the company’s website or follow its social media accounts.